- Home
- CURR vs CPIX Comparison
CURR vs CPIX Comparison
Compare CURR & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- CPIX
- Stock Information
- Founded
- CURR 2013
- CPIX 1999
- Country
- CURR Singapore
- CPIX United States
- Employees
- CURR N/A
- CPIX N/A
- Industry
- CURR Business Services
- CPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- CPIX Health Care
- Exchange
- CURR Nasdaq
- CPIX Nasdaq
- Market Cap
- CURR 74.0M
- CPIX 68.7M
- IPO Year
- CURR N/A
- CPIX 2009
- Fundamental
- Price
- CURR $0.60
- CPIX $5.28
- Analyst Decision
- CURR Strong Buy
- CPIX
- Analyst Count
- CURR 1
- CPIX 0
- Target Price
- CURR $3.50
- CPIX N/A
- AVG Volume (30 Days)
- CURR 2.0M
- CPIX 38.4K
- Earning Date
- CURR 05-20-2025
- CPIX 05-06-2025
- Dividend Yield
- CURR N/A
- CPIX N/A
- EPS Growth
- CURR N/A
- CPIX N/A
- EPS
- CURR N/A
- CPIX N/A
- Revenue
- CURR $43,386,858.00
- CPIX $41,083,299.00
- Revenue This Year
- CURR N/A
- CPIX N/A
- Revenue Next Year
- CURR $17.98
- CPIX N/A
- P/E Ratio
- CURR N/A
- CPIX N/A
- Revenue Growth
- CURR N/A
- CPIX 5.82
- 52 Week Low
- CURR $0.44
- CPIX $1.04
- 52 Week High
- CURR $7.08
- CPIX $7.25
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- CPIX 53.74
- Support Level
- CURR N/A
- CPIX $4.81
- Resistance Level
- CURR N/A
- CPIX $6.21
- Average True Range (ATR)
- CURR 0.00
- CPIX 0.50
- MACD
- CURR 0.00
- CPIX -0.00
- Stochastic Oscillator
- CURR 0.00
- CPIX 38.00
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.